281 patents currently held
36 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
28
Ending by 2030
Dec 2026
Next term end
175
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2035 · High confidence
Also notable
Ends Jan 2037 · High confidence
Also notable
Ends Jun 2034 · High confidence
Also notable
Ends Dec 2033 · High confidence
Also notable
Ends Sep 2036 · High confidence
Also notable
Ends Jul 2036 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends Nov 2041 · High confidence
Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
US 9,856,318
Cited by 74 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Compositions and Methods for Treating Malignant, Autoimmune and Inflammatory Diseases
US 10,828,318
Cited by 47 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037.
Plant with Altered Content of Steroidal Alkaloids
US 10,806,119
Cited by 27 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2034.
Molecular Sensor and Methods of Use Thereof
US 9,696,310
Cited by 29 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
CYP76AD1-Beta Clade Polynucleotides, Polypeptides, and Uses Thereof
US 10,767,201
Cited by 16 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.
Genetically Modified Anti-Third Party Central Memory T Cells and Use of Same in Immunotherapy
US 11,179,448
Cited by 13 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Combination Therapy for a Stable and Long Term Engraftment
US 10,369,172
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
System and Method for Orientating Capture of Ultrasound Images
US 11,593,638
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041.
Formerly held, still cited
Notable
Ends Jul 2028 · High confidence
The most cited patent in this portfolio, cited by 167 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
now held by Brainsway, Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 6 fees due Dec 2 to 30, 2026 · next Dec 2
- 2 fees due Jan 2 to 23, 2027 · next Jan 2
- 5 fees due Feb 6 to 22, 2027 · next Feb 6
- 3 fees due Mar 5 to 19, 2027 · next Mar 5
- 10 fees due Apr 1 to 29, 2027 · next Apr 1
- 4 fees due May 3 to 19, 2027 · next May 3
- 10 fees due Jun 5 to 30, 2027 · next Jun 5
- 8 fees due Jul 7 to 30, 2027 · next Jul 7
- 10 fees due Aug 4 to 20, 2027 · next Aug 4
- 6 fees due Sep 5 to 22, 2027 · next Sep 5
- 9 fees due Oct 2 to 30, 2027 · next Oct 2
- 2 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
- Nov 13Assignment recorded on 2 records: Ichilov Tech Ltd. to Yeda Research and Development Co. Ltd. Recorded Nov 13, 2026, executed Jun 4, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76743, frame 336.
- Oct 16Assignment recorded on 1 record: Globerson Levin, Anat and 2 others to Yeda Research and Development Co. Ltd. Recorded Oct 16, 2026, executed May 3, 2022. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76413, frame 244.
- 11 of the patents on this record were granted since Aug 21, 2026
- 5 terms have ended since Aug 21, 2026
What they patent
The largest of its 175 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,388,954 | Stabilising Formulation for Immunoglobulin G Compositions in Liquid Form and in Lyophilised Form In force · High confidence | In force | High confidence | |
| US 7,897,840 | Salt Responsive Genes Useful for Generating Salt Resistant Transgenic Plants In force · High confidence | In force | High confidence | |
| US 10,258,651 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 11,406,670 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 10,689,415 | Conjugates of RGD Peptides and (BACTERIO)CHLOROPHYLL Photosensitizers In force · Medium confidence | In force | Medium confidence | |
| US 7,947,672 | Water-Soluble Anionic Bacteriochlorophyll Derivatives and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 8,067,008 | Peptide Inhibitors for Mediating Stress Responses In force · High confidence | In force | High confidence | |
| US 9,631,175 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 11,326,147 | Redirected, Genetically-Engineered T Regulatory Cells and Their Use in Suppression of Autoimmune and Inflammatory Disease In force · High confidence | In force | High confidence | |
| US 8,486,653 | Antibodies and Pharmaceutical Compositions Containing Same Useful for Inhibiting Activity of Metalloproteins In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 281: 36 patents in force now held by others · 343 patents ended · 203 applications pending · 472 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.